home / stock / kttaw / kttaw quote
Last: | $0.0163 |
---|---|
Change Percent: | 0.0% |
Open: | $0.0163 |
Close: | $0.0163 |
High: | $0.0163 |
Low: | $0.0163 |
Volume: | 100 |
Last Trade Date Time: | 07/26/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$0.0163 | $0.0163 | $0.0163 | $0.0163 | $0.0163 | 100 | 07-26-2024 |
$0.0185 | $0 | $0.0185 | $0 | $0 | 1 | 07-25-2024 |
$0.0185 | $0.0185 | $0.0185 | $0.0185 | $0.0185 | 11,942 | 07-23-2024 |
$0.018 | $0.018 | $0.018 | $0.018 | $0.018 | 102 | 07-22-2024 |
$0.0126 | $0.0126 | $0.0126 | $0.012701 | $0.0126 | 8,250 | 07-17-2024 |
$0.0178 | $0.0178 | $0.0178 | $0.0178 | $0.0178 | 261 | 07-09-2024 |
$0.0178 | $0.0177 | $0.0178 | $0.0178 | $0.0165 | 4,490 | 07-04-2024 |
$0.0178 | $0.0177 | $0.0178 | $0.0178 | $0.016514 | 4,490 | 07-03-2024 |
$0.0111 | $0.0111 | $0.0111 | $0.0111 | $0.0111 | 6,360 | 07-01-2024 |
$0.0199 | $0.0199 | $0.0199 | $0.0199 | $0.0199 | 600 | 06-26-2024 |
$0.011 | $0.011 | $0.011 | $0.011 | $0.0109 | 15,200 | 06-24-2024 |
$0.017 | $0.016899 | $0.017 | $0.017 | $0.016899 | 5,000 | 06-21-2024 |
$0.0116 | $0.0116 | $0.0116 | $0.0116 | $0.0116 | 15,000 | 06-20-2024 |
$0.0126 | $0.0126 | $0.0126 | $0.0126 | $0.0126 | 10,001 | 06-17-2024 |
$0.0116 | $0.0125 | $0.0116 | $0.0125 | $0.0115 | 22,124 | 06-13-2024 |
$0.0158 | $0.0158 | $0.0158 | $0.0158 | $0.0158 | 7,781 | 06-12-2024 |
$0.0134 | $0.0134 | $0.0134 | $0.0134 | $0.0131 | 25,400 | 06-05-2024 |
$0.018 | $0 | $0.018 | $0 | $0 | 50 | 06-04-2024 |
$0.018 | $0.018 | $0.018 | $0.018 | $0.018 | 885 | 06-03-2024 |
$0.01655 | $0.0185 | $0.01655 | $0.0185 | $0.0128 | 3,158 | 05-29-2024 |
News, Short Squeeze, Breakout and More Instantly...
Pasithea Therapeutics Corp. Warrant Company Name:
KTTAW Stock Symbol:
NASDAQ Market:
Pasithea Therapeutics Corp. Warrant Website:
MIAMI, June 13, 2024 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, for the treatment of neurofibromatosis typ...
-- PAS-004 inhibition of in vitro NRAS cell lines does not plateau in contrast to approved MEK inhibitors -- -- PAS-004 inhibition of in vitro NRAS cell lines is greater than selumetinib and binimetinib and similar to trametinib -- -- PAS-004 shows superior activity versus selumetinib and...
SOUTH SAN FRANCISCO, Calif. and MIAMI, April 29, 2024 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor for the tr...